PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
USA - NASDAQ:PTCT - US69366J2006 - Common Stock
65.95 USD
-0.87 (-1.3%)
65.95 USD
0 (0%)
Taking everything into account, PTCT scores 6 out of 10 in our fundamental rating. PTCT was compared to 536 industry peers in the Biotechnology industry. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here. PTCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes PTCT very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year PTCT was profitable.
PTCT had a positive operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
PTCT has a better Return On Assets (23.89%) than 97.39% of its industry peers.
With an excellent Return On Invested Capital value of 34.54%, PTCT belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROIC | 34.54% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PTCT (35.65%) is better than 96.83% of its industry peers.
PTCT has a better Operating Margin (49.70%) than 99.44% of its industry peers.
PTCT has a better Gross Margin (97.09%) than 96.64% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PTCT has been increased compared to 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PTCT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.13 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
PTCT has a better Altman-Z score (2.13) than 65.30% of its industry peers.
The Debt to FCF ratio of PTCT is 3.44, which is a good value as it means it would take PTCT, 3.44 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.44, PTCT belongs to the best of the industry, outperforming 93.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Altman-Z | 2.13 |
ROIC/WACC4.39
WACC7.87%
2.3 Liquidity
PTCT has a Current Ratio of 3.62. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Current ratio of 3.62. This is comparable to the rest of the industry: PTCT outperforms 42.35% of its industry peers.
PTCT has a Quick Ratio of 3.57. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Quick ratio (3.57) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 226.85% over the past year.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 96.00%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
3.2 Future
Based on estimates for the next years, PTCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.99% on average per year.
Based on estimates for the next years, PTCT will show a quite strong growth in Revenue. The Revenue will grow by 16.08% on average per year.
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.63 indicates a reasonable valuation of PTCT.
Compared to the rest of the industry, the Price/Earnings ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 97.39% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.40. PTCT is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.63 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 98.32% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaper than 98.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.51 | ||
| EV/EBITDA | 5.25 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 24.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y18.49%
EPS Next 3Y24.02%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.95
-0.87 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.79%
Inst Owner Change-0.59%
Ins Owners0.7%
Ins Owner Change1.33%
Market Cap5.24B
Analysts78.26
Price Target67.93 (3%)
Short Float %9.42%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2383.16%
Min EPS beat(2)23.33%
Max EPS beat(2)4742.99%
EPS beat(4)3
Avg EPS beat(4)1137.62%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)4
Avg EPS beat(8)542.76%
EPS beat(12)4
Avg EPS beat(12)346.13%
EPS beat(16)4
Avg EPS beat(16)252.2%
Revenue beat(2)2
Avg Revenue beat(2)293.95%
Min Revenue beat(2)2.58%
Max Revenue beat(2)585.33%
Revenue beat(4)3
Avg Revenue beat(4)147.39%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.39%
Revenue beat(12)7
Avg Revenue beat(12)50.4%
Revenue beat(16)10
Avg Revenue beat(16)39.02%
PT rev (1m)0%
PT rev (3m)6.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.55%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)27.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-0.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.63 | ||
| Fwd PE | N/A | ||
| P/S | 2.97 | ||
| P/FCF | 7.51 | ||
| P/OCF | 7.43 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.25 |
EPS(TTM)5.67
EY8.6%
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)8.78
FCFY13.31%
OCF(TTM)8.87
OCFY13.45%
SpS22.22
BVpS-2.6
TBVpS-5.45
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROCE | 43.72% | ||
| ROIC | 34.54% | ||
| ROICexc | 4029.4% | ||
| ROICexgc | N/A | ||
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% | ||
| FCFM | 39.52% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 26.13% | ||
| Cap/Sales | 0.42% | ||
| Interest Coverage | 203.36 | ||
| Cash Conversion | 77.86% | ||
| Profit Quality | 110.85% | ||
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 | ||
| Altman-Z | 2.13 |
F-Score8
WACC7.87%
ROIC/WACC4.39
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%
EBIT growth 1Y546.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.42%
EBIT Next 3Y50.48%
EBIT Next 5YN/A
FCF growth 1Y350.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A